EA199900006A1 - Препарат и способ для лечения застоной сердечной недостаточности - Google Patents

Препарат и способ для лечения застоной сердечной недостаточности

Info

Publication number
EA199900006A1
EA199900006A1 EA199900006A EA199900006A EA199900006A1 EA 199900006 A1 EA199900006 A1 EA 199900006A1 EA 199900006 A EA199900006 A EA 199900006A EA 199900006 A EA199900006 A EA 199900006A EA 199900006 A1 EA199900006 A1 EA 199900006A1
Authority
EA
Eurasian Patent Office
Prior art keywords
heart failure
preparation
treatment
strong heart
prolonged
Prior art date
Application number
EA199900006A
Other languages
English (en)
Russian (ru)
Inventor
Джон Л. Макнэй
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA199900006A1 publication Critical patent/EA199900006A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EA199900006A 1996-06-06 1999-01-06 Препарат и способ для лечения застоной сердечной недостаточности EA199900006A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65946396A 1996-06-06 1996-06-06
PCT/US1997/009914 WO1997046241A1 (en) 1996-06-06 1997-06-05 Formulation and method for treating congestive heart failure

Publications (1)

Publication Number Publication Date
EA199900006A1 true EA199900006A1 (ru) 1999-06-24

Family

ID=24645503

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900006A EA199900006A1 (ru) 1996-06-06 1999-01-06 Препарат и способ для лечения застоной сердечной недостаточности

Country Status (17)

Country Link
EP (1) EP0914128A1 (ko)
JP (1) JP2000511906A (ko)
KR (1) KR20000016406A (ko)
CN (1) CN1226166A (ko)
AU (1) AU3233197A (ko)
BR (1) BR9709546A (ko)
CA (1) CA2256720A1 (ko)
CZ (1) CZ397698A3 (ko)
EA (1) EA199900006A1 (ko)
HU (1) HUP0003885A2 (ko)
IL (1) IL126966A0 (ko)
NO (1) NO985695L (ko)
PL (1) PL330637A1 (ko)
TR (1) TR199802496T2 (ko)
WO (1) WO1997046241A1 (ko)
YU (1) YU55998A (ko)
ZA (1) ZA974978B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19815411A1 (de) * 1998-04-06 1999-10-07 Solvay Pharm Gmbh Thermogenese stimulierend wirksame Arzneimittel
WO2000044355A1 (en) * 1999-01-29 2000-08-03 Eli Lilly And Company Moxonidine salts
SK10082001A3 (sk) * 1999-02-01 2002-04-04 Solvay Pharmaceuticals Gmbh Použitie moxonidínu na liečbu po srdcovom infarkte
DE602006018139D1 (de) * 2006-08-31 2010-12-23 Chemagis Ltd Verwendung der Monoxidinssalze zur Reinigung von Monoxidin
KR100812287B1 (ko) * 2007-01-03 2008-03-13 주식회사 챠콜코리아 내면에 반사층을 갖는 신호등 갓

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
DE3617158C2 (de) * 1986-05-22 1994-10-06 Lohmann Therapie Syst Lts Transdermales Arzneimittel
DE3729299A1 (de) * 1987-09-02 1989-03-23 Beiersdorf Ag Transdermales therapeutisches system
DE3904795C2 (de) * 1989-02-17 2000-10-12 Lilly Pharma Produktion Gmbh & Pharmazeutisches Präparat und dessen Verwendung
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
DE4423177A1 (de) * 1994-07-01 1996-01-04 Kali Chemie Pharma Gmbh Antihyperglykämisch wirksame Arzneimittel
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal

Also Published As

Publication number Publication date
EP0914128A1 (en) 1999-05-12
KR20000016406A (ko) 2000-03-25
JP2000511906A (ja) 2000-09-12
NO985695D0 (no) 1998-12-04
AU3233197A (en) 1998-01-05
IL126966A0 (en) 1999-09-22
ZA974978B (en) 1998-12-07
YU55998A (en) 1999-11-22
HUP0003885A2 (hu) 2001-04-28
NO985695L (no) 1999-02-04
BR9709546A (pt) 1999-08-10
CA2256720A1 (en) 1997-12-11
WO1997046241A1 (en) 1997-12-11
TR199802496T2 (xx) 1999-02-22
CZ397698A3 (cs) 1999-05-12
CN1226166A (zh) 1999-08-18
PL330637A1 (en) 1999-05-24

Similar Documents

Publication Publication Date Title
EA199801044A1 (ru) Модуляторы регенерации тканей
AR052921A1 (es) Uso de ranolazina para la preparacion de una composicion farmaceutica y composicion farmaceutica
DE69827001D1 (de) Gewebedezellularization
DE69738615D1 (de) Verwendung von glp-1 oder analogen zur behandlung von myokardischem infarkt
PT831882E (pt) Composicoes de segmentos de fibra de colagenio reconstituido e metodos de preparacao das mesmas
NO303425B1 (no) FremgangsmÕte for behandling av et kirurgisk metallimplantat
RU92016244A (ru) Производные сахарина-ингибиторы протеолитических ферментов
ZA966798B (en) Methods of reducing or maintaining reduced levels of blood lipids using OB protein compositions.
ATE239474T1 (de) Verwendung von levobupivacain
ATE421329T1 (de) Verwendung von aplidine zur behandlung von kardiovaskulären erkrankungen
ATA91797A (de) Eine das vwf-propeptid enthaltende pharmazeutische präparation
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
ATE201598T1 (de) Verwendung von moxonidin zur behandlung neuropathischer schmerzen
EA199900006A1 (ru) Препарат и способ для лечения застоной сердечной недостаточности
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
EA199800889A1 (ru) Способ предупреждения и/или лечения сердечной недостаточности и дисфункции желудочков антагонистами эндотелина, фармацевтическая композиция
DE69621786T2 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
DE69924979D1 (de) Behandlung von chronischen schmerzen
MY124071A (en) Treatment of viral disease in swine
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
EA199800535A1 (ru) Способ лечения боли
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
EA200001097A1 (ru) Стабильные композиции, содержащие левозимендан и альгиновую кислоту